Mastocytosis: Guidelines of the German Society for Allergology and Clinical Immunology and the German Dermatological Society;Mastozytose: Leitlinie der Deutschen Gesellschaft für Allergologie und Klinische Immunologie (DGAKI) und der Deutschen Dermatologischen Gesellschaft (DDG)

Allergologie

Volumn 32, Issue 6, 2009, Pages 199-213

  Hartmann, Karin ^a   Biedermann, T ^b   Brockow, K ^c   Grabbe, J ^d   Horny, H P ^e   Lippert, U ^f   Maurer, M ^g   Raithel, M ^h   Rietschel, E ^a   Rueff F ⁱ   Sotlar, K ⁱ  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e Institut für Pathologie   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CD2 ANTIGEN; CLADRIBINE; CORTICOSTEROID; CYTOKINE; HISTAMINE; IMATINIB; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOTRIENE; METHOTREXATE; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISOLONE; PROSTAGLANDIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; ANAMNESIS; ANAPHYLAXIS; ASCITES; BODY TEMPERATURE; BONE PAIN; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CODON; DISEASE CLASSIFICATION; EXON; FLUSHING; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; INCIDENCE; MACULOPAPULAR RASH; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; OSTEOPENIA; PATHOLOGIC FRACTURE; PHOTOTHERAPY; PROGNOSIS; PRURITUS; REMISSION; REVIEW; RISK ASSESSMENT; SARCOMA; SELF INJECTION; SKIN BIOPSY; STRESS; SYSTEMIC MASTOCYTOSIS; TELANGIECTASIA; URTICARIA PIGMENTOSA;

EID: 68449098536     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004; 103: 3222-3225. (Pubitemid 38451702)
2. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007; 110: 2331-2333.
3. Anstey A, Lowe DG, Kirby JD, Horton MA. Familial mastocytosis: a clinical, immunophenotypic, light and electron microscopic study. Br J Dermatol. 1991; 125: 583-587.
4. Biedermann T, Ruëff F, Sander CA, Przybilla B. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol. 1999; 141: 1110-1112. (Pubitemid 30046205)
5. Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003; 48: 508-516. (Pubitemid 36397011)
6. Bubnoff N von, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J. The systemic mastocytosis- specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia. 2005; 19: 1670-1671. (Pubitemid 43090414)
7. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, GillilandDG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348: 1201-1214. (Pubitemid 36359296)
8. Desborough JP, Taylor I, Hattersley A, Garden A, Wolff A, Bloom SR, Morgan M. Massive histamine release in a patient with systemic mastocytosis. Br J Anaesth. 1990; 65: 833-836.
9. Dodd NJ, Bond MG. Fatal anaphylaxis in systemic mastocytosis. J Clin Pathol. 1979; 32: 31-34.
10. Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cervero C, Lopez A, Marcos MA, Bellas C, Fernandez-Canadas S, Cuevas M, Sanchez A, Velasco JL, Navarro JL, Miguel JF. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998; 91: 2731-2736. (Pubitemid 28227522)
11. Födinger M, Fritsch G, Winkler K, Emminger W, MitterbauerG, Gadner H, Valent P, Mannhalter C. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood. 1994; 84: 2954-2959. (Pubitemid 24328084)
12. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993; 92: 1736-1744. (Pubitemid 23304537)
13. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A. KITmutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108: 2366-2372. (Pubitemid 44497521)
14. Garriga MM, Friedman MM, Metcalfe DD. Asurvey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol. 1988; 82: 425-432.
15. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006; 107: 752-759. (Pubitemid 43076402)
16. Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007; 92: 1451-1459. (Pubitemid 350144119)
17. Godt O, Proksch E, StreitV, Christophers E. Short- and long-term effectiveness of oral and bathPUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology. 1997; 195: 35-39. (Pubitemid 27326706)
18. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH,Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005; 106: 2865-2870. (Pubitemid 41510766)
19. Gysel Dvan, Oranje AP, Vermeiden I, de Lijster de Raadt J, Mulder PG, van Toorenenbergen AW. Value of urinary N-methylhistamine measurements in childhood mastocytosis. J Am Acad Dermatol. 1996; 35: 556-558. (Pubitemid 26427056)
20. Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol. 2001; 144: 682-695. (Pubitemid 32374769)
21. Hartmann K, Metcalfe DD. Pediatric mastocytosis. Hematol Oncol Clin North Am. 2000; 14: 625-640.
22. Hartmann K, Wardelmann E, Ma Y, Merkelbach- Bruse S, Preussner LM, Woolery C, Baldus SE, Heinicke T, Thiele J, Büttner R, Longley BJ. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005; 129: 1042-1046. (Pubitemid 41242694)
23. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR,Lechner K,Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive mastocytosis: report of five cases and review of the literature. Leuk Res. 2004; 28: 249-257. (Pubitemid 37550059)
24. Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998; 22: 1132-1140. (Pubitemid 28411072)
25. Hosking MP, Warner MA. Sudden intraoperative hypotension in a patient with asymptomatic urticaria pigmentosa. Anesth Analg. 1987; 66: 344-346.
26. Jordan JH, Fritsche-Polanz R, Sperr WR, Mitterbauer G, Födinger M, Schernthaner GH, Bankl HC, Gebhart W, Chott A, Lechner K, Valent P. A case of "smouldering" mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk Res. 2001; 25: 627-634.
27. King JJ, Crawford EA, Iwenofu OH, Fox EJ. Case report: pathologic long fracture in a patient with systemic mastocytosis. Clin Orthop. 2007; 459: 263-269. (Pubitemid 46878227)
28. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, Willemze R. Response to interferon alpha-2b in a patient with systemic mastocytosis. N Engl J Med. 1992; 326: 619-623.
29. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Vant Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Paasmans SG, Fijnheer R. Cladribine therapy for systemic mastocytosis. Blood. 2003; 102: 4270-4276.
30. Kosmider O, Denis N, Dubreuil P, Moreau- Gachelin F. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene. 2007; 26: 3904-3908. (Pubitemid 46878135)
31. Krokowski M, Sotlar K, Krauth MT, Födinger M, Valent P, Horny HP. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol. 2005; 124: 560-568. (Pubitemid 41395637)
32. Laroche M, Bret J, Brouchet A, Mazieres B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol. 2007; 26: 242-243. (Pubitemid 46020252)
33. Lippert U, Henz BM. Long-term effect of interferon alpha treatment in mastocytosis. Br J Dermatol. 1996; 134: 1164-1165. (Pubitemid 26183166)
34. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D,MaY. Activating and dominant inactivating. c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA. 1999; 96: 1609-1614. (Pubitemid 29098499)
35. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002; 99: 1741-1744. (Pubitemid 34533049)
36. Maric I, Robyn J, Metcalfe DD, FayMP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD. KITD816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007; 120: 680-687. (Pubitemid 47320757)
37. Mekori YA, Oh CK, Metcalfe DD. IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand. J Immunol. 1993; 151: 3775-3784.
38. Metcalfe DD. The treatment of mastocytosis: an overview. J Invest Dermatol. 1991; 96 (Suppl): 55S-56S.
39. Müller UR, Horat W, Wüthrich B, Conroy M, Reisman RE. Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J Allergy Clin Immunol. 1983; 72: 685-689. (Pubitemid 14210903)
40. Murphy M,Walsh D, Drumm B,Watson R. Bullous mastocytosis: a fatal outcome. Pediatr Dermatol. 1999; 16: 452-455.
41. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA. 1995; 92: 10560-10564.
42. Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant. 2006; 37: 353-358. (Pubitemid 43250468)
43. Oranje AP, Mulder PG, Heide R, Tank B, Riezebos P, van Toorenenbergen AW. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol. 2002; 27: 502-506. (Pubitemid 35278945)
44. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2008; 138: 12-30. (Pubitemid 46889785)
45. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KITD816Vmutation. Blood. 2007; 109: 315-322. (Pubitemid 46053072)
46. Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, VainchenkerW, Vernant JP, Tulliez M. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol. 1997; 96: 374-376. (Pubitemid 27077375)
47. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol. 1998; 57: 24-28. (Pubitemid 28047194)
48. Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, Sun J, Senitzer D, Slovak ML. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res. 2007; 31: 261-265. (Pubitemid 44854181)
49. Pullarkat VA, Pullarkat ST, Calverley DC, Brynes RK. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816Hys. Am J Hematol. 2000; 65: 307-309.
50. Purtill D, Cooney J, Sinniah R, Carnley B, Cull G, Augustson B, Cannell P. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol. 2008; 80: 456-458.
51. Ronnov-Jessen D, Lovgreen Nielsen P, Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant. 1991; 8: 413-415.
52. Rosbotham JL, Malik NM, Syrris P, Jeffery S, Bedlow A, Gharraie S, Murday VA, Holden CA, Carter ND. Lack of c-kit mutation in familial urticaria pigmentosa. Br J Dermatol. 1999; 140: 849-852. (Pubitemid 29238456)
53. Ruëff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol. 2006; 6: 284-288.
54. Sagher F, Even-Paz Z. Incidence of mastocytosis. In: Sagher F, Even-Paz Z (eds). Mastocytosis and the mast cell. Basel - New York: Karger; 1967, 14-17.
55. Schernthaner GH, Jordan JH, Ghannadan M, Agis H, Bevec D, Nunez R, Escribano L, Majdic O, Willheim M, Worda C, Printz D, Fritsch G, Lechner K, Valent P. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001; 98: 3784-3792.
56. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KITisoforms associated with human malignancies. Cancer Res. 2006; 66: 473-481. (Pubitemid 43166056)
57. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006; 108: 286-291. (Pubitemid 43990640)
58. Shah PY, Sharma V, Worobec AS, Metcalfe DD, Zwick DC. Congenital bullous mastocytosis with myeloproliferative disorder and c-kit mutation. J Am Acad Dermatol. 1998; 39: 119-121. (Pubitemid 28332319)
59. Sonneck K, Florian S, Mullauer L, Wimazal F, Födinger M, Sperr WR, Valent P. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2006; 142: 158-164. (Pubitemid 46095928)
60. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am. 2000; 14: 537-555.
61. Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bultmann B. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003; 162: 737-746. (Pubitemid 36237482)
62. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, Semper H, Simonitsch-Klupp I, Horny HP, Valent P. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002; 128: 136-141. (Pubitemid 34639022)
63. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001; 344: 307-309. (Pubitemid 32108542)
64. Tefferi A, Pardanani A, Li CY, Klion AD, Akin C, Nutman TB. Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? Blood. 2003; 102: 3073-3074.
65. Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA. 1991; 88: 6382-6386. (Pubitemid 21914950)
66. Tzankov A, Sotlar K, Muhlematter D, Theocharides A, Went P, Jotterand M, Horny HP, Dirnhofer S. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J Clin Pathol. 2008; 61: 958-961.
67. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardimann JW, Bennett JM. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25: 603-625. (Pubitemid 32506768)
68. Valent P, Horny HP, Li CY, Longley BJ, Metcalfe DD, Parwaresch RM, Bennett JM. Mastocytosis (mast cell disease). In: Jaffe ED, Harris NL, Stein H,VardimanJW(eds).World Health Organization Classification of Tumours. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001, 291-302.
69. Vendome J, Letard S, Martin F, Svinarchuk F, Dubreuil P, Auclair C, Le Bret M. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005; 48: 6194-6201. (Pubitemid 41428974)
70. Verstovsek S, Tefferi A, Cortes J, OBrien S, Garcia- Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosomenegative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008; 14: 3906-3915.
71. Vlieg-Boerstra BJ, van der Heide S, Oude Elberink JN, Kluin-Nelemans JC, Dubois AE. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med. 2005; 63: 244-249.
72. Wagner N, Fritze D, Przybilla B, Hagedorn M, Ruëff F. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol. 2008; 146: 162-163. (Pubitemid 351685480)
73. Weber A, Knop J, Maurer M. Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br J Dermatol. 2003; 148: 224-228. (Pubitemid 36278960)
74. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001; 25: 519-528. (Pubitemid 32506758)
75. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am. 2000; 14: 659-687.
76. Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma. 1996; 22: 501-508. (Pubitemid 26341017)
77. Yanagihori H, Oyama N, Nakamura K, Kaneko F. c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn. 2005; 7: 252-257. (Pubitemid 40668308)
78. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NC, Cavenagh JD. A novel K509I mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2006; 30: 373-378. (Pubitemid 43254957)